The Effect of Tranexamic Acid on Calculated Total Blood Loss in Anticoagulated patients undergoing Total Shoulder Arthroplasty

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Shoulder Pain
  • Age: Between 18 years - 85 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants who are 18 years or older
    2. Undergoing scheduled primary anatomic total shoulder arthroplasty
    3. Undergoing scheduled primary reverse total shoulder arthroplasty
    4. Participants who consent to be randomized
    5. Preoperative use of anticoagulant or antiplatelet therapy within 10 days prior to surgery:
      • Coumadin (Warfarin)
      • Heparin
      • Low molecular weight heparin
      • Factor Xa inhibitors
        • Apixaban (Eliquis)
        • Rivarixaban (Xatelto)
        • Edoxaban (Savaysa)
        • Dabigatran (Pradaxa)
      • Clopidogrel (Plavix)
      • Prasugrel (Effient)
      • Ticagrelor (Brilinta)

You may not be eligible for this study if the following are true:

    1. Younger than 18
    2. Pregnant or lactating
    3. Participants who are allergic to tranexamic acid
    4. Those scheduled for revision total shoulder arthroplasty
    5. Participants with proximal humerus fracture or fracture sequelae
    6. Participants who use estrogen containing medications (i.e. oral contraceptive pills)
    7. Those who have acquired disturbances of color vision
    8. Participants with a history of any of the following diagnosis:
      • Subarachnoid hemorrhage
      • Active intravascular clotting
      • Severe pulmonary disease
      • Plasma creatinine > 115 µmol/L in males, > 100 µmol/L in females, or hepatic failure
      • Preoperative anemia
    9. Those who refuse blood products
    10. Participants undergoing hormone replacement therapy
    11. Diagnosed or self-reported cognitive dysfunction
    12. Unable to understand or follow instructions
    13. Participants with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease
    14. BMI over 50
    15. Any patient that the investigators feel cannot comply with all study related procedures.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.